Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association [J]. Hepatology, 2012, 55(6):2005.
[2]
Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis:epidemiology, pathogenesis, clinical presentation and treatment [J]. Dig Dis, 2012, 30(2):158.
[3]
Day C, James O. Steatohepatitis:a tale of two " hits" [J]. Gastroenterology, 1998, 114(4):842.
[4]
Birkenfeld A L, Shulman G I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes [J]. Hepatology, 2014, 59(2):713.
Day C P. Non-alcoholic steatohepatitis (NASH):where are we now and where are we going [J]. Gut, 2002, 50:585.
[10]
Zhang H, Li Y, Wang S, et al. LPS-induced NF-kappa B activation requires Ca2+ as a mediator in isolated pancreatic acinar cells of rat [J]. Chin Med J (Engl), 2003, 116:1662.
[11]
Thorpe L B, Goldie M, Dolan S. Central and local administration of Gingko biloba extract EGb 761 inhibits thermal hyperalgesia and inflammation in the rat carrageenan model [J]. Anesth Analg, 2011,112(5):1226.
[12]
Chen Y J, Tsai K S, Chiu C Y, et al. EGb761 inhibits inflammatory responses in human chondrocytes and shows chondroprotection in osteoarthritic rat knee [J]. J Orthop Res, 2013, 31(7):1032.
[13]
Huang C H, Yang M L, Tsai C H, et al. Ginkgo biloba leaves extract (EGb 761) attenuates lipopolysaccharide-induced acute lung injury via inhibition of oxidative stress and NF-κB-dependent matrix metalloproteinase-9 pathway [J]. Phytomedicine, 2013, 20(3/4):303.
[14]
Shen J, Lee W, Gu Y, et al. Ginkgo biloba extract (EGb761) inhibits mitochondria-dependent caspase pathway and prevents apoptosis in hypoxia-reoxygenated cardiomyocytes [J]. Chin Med 2011, 6:8.
[15]
Liu W, Li S Y, Huang X E, et al. Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum [J]. Asian Pac J Cancer Prev, 2012, 13(5):2409.
Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease [J]. Hepatology, 2009, 49(6):1877.
[18]
Suzuki T, Hara H. Quercetin enhances intestinal barrier function through the assembly of zonnula occludens-2, Occludin, and Claudin-1 and the expression of Claudin-4 in Caco-2 cells [J]. J Nutr, 2009, 139(5):965.
[19]
Suzuki T, Tanabe S, Hara H. Kaempferol enhances intestinal barrier function through the cytoskeletal association and expression of tight junction proteins in Caco-2 cells [J]. J Nutr, 2011, 141(1):87.
[20]
Abu-Shanab A, Quigley E M. The role of the gut microbiota in nonalcoholic fatty liver disease [J]. Nat Rev Gastroenterol Hepatol, 2010, 7:691.
[21]
Zhang C, Zhang M, Wang S, et al. Interactions between gut microbiota,host genetics and diet relevant to development of metabolic syndromes in mice [J]. ISME J, 2010, 4(2):232.
